tiprankstipranks
Trending News
More News >
Charles River Laboratories Intl (CRL)
:CRL
US Market

Charles River Labs (CRL) Stock Forecast & Price Target

Compare
553 Followers
See the Price Targets and Ratings of:

CRL Analyst Ratings

Moderate Buy
14Ratings
Moderate Buy
4 Buy
10 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Charles
River Labs
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CRL Stock 12 Month Forecast

Average Price Target

$157.23
▲(16.43%Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Charles River Labs in the last 3 months. The average price target is $157.23 with a high forecast of $182.00 and a low forecast of $100.00. The average price target represents a 16.43% change from the last price of $135.04.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"99":"$99","135":"$135","171":"$171","207":"$207","243":"$243"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":182,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$182.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":157.23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$157.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[99,135,171,207,243],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,116.89,121.89846153846153,126.90692307692308,131.91538461538462,136.92384615384614,141.9323076923077,146.94076923076923,151.94923076923078,156.9576923076923,161.96615384615384,166.9746153846154,171.9830769230769,176.99153846153845,{"y":182,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,116.89,119.99307692307693,123.09615384615384,126.19923076923077,129.3023076923077,132.4053846153846,135.50846153846152,138.61153846153846,141.71461538461537,144.8176923076923,147.92076923076922,151.02384615384614,154.12692307692305,{"y":157.23,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,116.89,115.59076923076923,114.29153846153847,112.99230769230769,111.69307692307693,110.39384615384616,109.09461538461538,107.79538461538462,106.49615384615385,105.19692307692307,103.89769230769231,102.59846153846154,101.29923076923077,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":232.69,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":208.44,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.24,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":242.84,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":197.75,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":194.08,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":180.96,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":201.25,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":184.6,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":164.76,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":165.31,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":145.99,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":116.89,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$182.00Average Price Target$157.23Lowest Price Target$100.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on CRL
TipRanks AITipRanks
Not Ranked
TipRanks
$145
Hold
7.38%
Upside
Reiterated
05/22/25
Charles River Labs' overall stock score reflects robust cash flow and strategic leadership changes, countered by valuation concerns and profitability challenges. While the earnings call and corporate events provide optimism, revenue and profitability declines weigh on the stock's outlook.
Redburn Atlantic Analyst forecast on CRL
Jamie ClarkRedburn Atlantic
Redburn Atlantic
$188$182
Buy
34.77%
Upside
Upgraded
05/23/25
Charles River upgraded to Buy from Neutral at Redburn AtlanticCharles River upgraded to Buy from Neutral at Redburn Atlantic
TD Cowen
$105$179
Buy
32.55%
Upside
Upgraded
05/14/25
Unlocking Value: Strategic Divestitures and Market Leadership at Charles River Labs
Morgan Stanley Analyst forecast on CRL
Tejas SavantMorgan Stanley
Morgan Stanley
$184$168
Hold
24.41%
Upside
Reiterated
05/09/25
Mixed Signals and Uncertainty: Hold Rating on Charles River Labs Amid Strong DSA Performance and RMS Challenges
UBS
$185$150
Hold
11.08%
Upside
Reiterated
05/08/25
Charles River Labs (CRL) PT Lowered to $150 at UBSUBS analyst Dan Leonard lowered the price target on Charles River Labs (NYSE: CRL) to $150.00 (from $185.00) while maintaining a Neutral rating.
Robert W. Baird Analyst forecast on CRL
Eric ColdwellRobert W. Baird
Robert W. Baird
$118$140
Hold
3.67%
Upside
Reiterated
05/08/25
Charles River price target raised to $140 from $118 at BairdCharles River price target raised to $140 from $118 at Baird
Barclays Analyst forecast on CRL
Luke SergottBarclays
Barclays
$145$155
Hold
14.78%
Upside
Reiterated
05/08/25
Barclays Keeps Their Hold Rating on Charles River Labs (CRL)
William Blair Analyst forecast on CRL
Max SmockWilliam Blair
William Blair
Hold
Reiterated
05/07/25
Charles River Labs: Balancing Strong Q1 Performance with Market Uncertainties - Hold Rating Maintained
J.P. Morgan Analyst forecast on CRL
Casey WoodringJ.P. Morgan
J.P. Morgan
$165$145
Hold
7.38%
Upside
Reiterated
05/07/25
Analysts Conflicted on These Healthcare Names: EyePoint Pharmaceuticals (NASDAQ: EYPT), Charles River Labs (NYSE: CRL) and Innoviva (NASDAQ: INVA)
Deutsche Bank  Analyst forecast on CRL
Justin BowersDeutsche Bank
Deutsche Bank
$140$180
Buy
33.29%
Upside
Reiterated
05/07/25
Charles River Labs (CRL) PT Raised to $180 at Deutsche BankDeutsche Bank analyst Justin Bowers raised the price target on Charles River Labs (NYSE: CRL) to $180.00 (from $140.00) while maintaining a Buy rating.
Evercore ISI
$135$170
Buy
25.89%
Upside
Upgraded
05/07/25
Positive Report for Charles River Labs (CRL) from Evercore ISI
Jefferies Analyst forecast on CRL
David WindleyJefferies
Jefferies
$169$100
Hold
-25.95%
Downside
Reiterated
04/21/25
Charles River Labs (CRL) PT Lowered to $100 at JefferiesJefferies analyst David Windley lowered the price target on Charles River Labs (NYSE: CRL) to $100.00 (from $169.00) while maintaining a Hold rating.
Bank of America Securities Analyst forecast on CRL
Michael RyskinBank of America Securities
Bank of America Securities
$185$150
Hold
11.08%
Upside
Reiterated
04/14/25
Charles River price target lowered to $150 from $185 at BofACharles River price target lowered to $150 from $185 at BofA
Mizuho Securities Analyst forecast on CRL
Ann HynesMizuho Securities
Mizuho Securities
$175$155
Hold
14.78%
Upside
Reiterated
04/09/25
Charles River price target lowered to $155 from $175 at MizuhoCharles River price target lowered to $155 from $175 at Mizuho
Goldman Sachs Analyst forecast on CRL
Matthew SykesGoldman Sachs
Goldman Sachs
$190$170
Hold
25.89%
Upside
Downgraded
03/21/25
Charles River Labs (CRL) was downgraded to a Hold Rating at Goldman Sachs
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on CRL
TipRanks AITipRanks
Not Ranked
TipRanks
$145
Hold
7.38%
Upside
Reiterated
05/22/25
Charles River Labs' overall stock score reflects robust cash flow and strategic leadership changes, countered by valuation concerns and profitability challenges. While the earnings call and corporate events provide optimism, revenue and profitability declines weigh on the stock's outlook.
Redburn Atlantic Analyst forecast on CRL
Jamie ClarkRedburn Atlantic
Redburn Atlantic
$188$182
Buy
34.77%
Upside
Upgraded
05/23/25
Charles River upgraded to Buy from Neutral at Redburn AtlanticCharles River upgraded to Buy from Neutral at Redburn Atlantic
TD Cowen
$105$179
Buy
32.55%
Upside
Upgraded
05/14/25
Unlocking Value: Strategic Divestitures and Market Leadership at Charles River Labs
Morgan Stanley Analyst forecast on CRL
Tejas SavantMorgan Stanley
Morgan Stanley
$184$168
Hold
24.41%
Upside
Reiterated
05/09/25
Mixed Signals and Uncertainty: Hold Rating on Charles River Labs Amid Strong DSA Performance and RMS Challenges
UBS
$185$150
Hold
11.08%
Upside
Reiterated
05/08/25
Charles River Labs (CRL) PT Lowered to $150 at UBSUBS analyst Dan Leonard lowered the price target on Charles River Labs (NYSE: CRL) to $150.00 (from $185.00) while maintaining a Neutral rating.
Robert W. Baird Analyst forecast on CRL
Eric ColdwellRobert W. Baird
Robert W. Baird
$118$140
Hold
3.67%
Upside
Reiterated
05/08/25
Charles River price target raised to $140 from $118 at BairdCharles River price target raised to $140 from $118 at Baird
Barclays Analyst forecast on CRL
Luke SergottBarclays
Barclays
$145$155
Hold
14.78%
Upside
Reiterated
05/08/25
Barclays Keeps Their Hold Rating on Charles River Labs (CRL)
William Blair Analyst forecast on CRL
Max SmockWilliam Blair
William Blair
Hold
Reiterated
05/07/25
Charles River Labs: Balancing Strong Q1 Performance with Market Uncertainties - Hold Rating Maintained
J.P. Morgan Analyst forecast on CRL
Casey WoodringJ.P. Morgan
J.P. Morgan
$165$145
Hold
7.38%
Upside
Reiterated
05/07/25
Analysts Conflicted on These Healthcare Names: EyePoint Pharmaceuticals (NASDAQ: EYPT), Charles River Labs (NYSE: CRL) and Innoviva (NASDAQ: INVA)
Deutsche Bank  Analyst forecast on CRL
Justin BowersDeutsche Bank
Deutsche Bank
$140$180
Buy
33.29%
Upside
Reiterated
05/07/25
Charles River Labs (CRL) PT Raised to $180 at Deutsche BankDeutsche Bank analyst Justin Bowers raised the price target on Charles River Labs (NYSE: CRL) to $180.00 (from $140.00) while maintaining a Buy rating.
Evercore ISI
$135$170
Buy
25.89%
Upside
Upgraded
05/07/25
Positive Report for Charles River Labs (CRL) from Evercore ISI
Jefferies Analyst forecast on CRL
David WindleyJefferies
Jefferies
$169$100
Hold
-25.95%
Downside
Reiterated
04/21/25
Charles River Labs (CRL) PT Lowered to $100 at JefferiesJefferies analyst David Windley lowered the price target on Charles River Labs (NYSE: CRL) to $100.00 (from $169.00) while maintaining a Hold rating.
Bank of America Securities Analyst forecast on CRL
Michael RyskinBank of America Securities
Bank of America Securities
$185$150
Hold
11.08%
Upside
Reiterated
04/14/25
Charles River price target lowered to $150 from $185 at BofACharles River price target lowered to $150 from $185 at BofA
Mizuho Securities Analyst forecast on CRL
Ann HynesMizuho Securities
Mizuho Securities
$175$155
Hold
14.78%
Upside
Reiterated
04/09/25
Charles River price target lowered to $155 from $175 at MizuhoCharles River price target lowered to $155 from $175 at Mizuho
Goldman Sachs Analyst forecast on CRL
Matthew SykesGoldman Sachs
Goldman Sachs
$190$170
Hold
25.89%
Upside
Downgraded
03/21/25
Charles River Labs (CRL) was downgraded to a Hold Rating at Goldman Sachs
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Charles River Labs

1 Month
xxx
Success Rate
5/10 ratings generated profit
50%
Average Return
+1.40%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +1.40% per trade.
3 Months
xxx
Success Rate
6/10 ratings generated profit
60%
Average Return
+4.33%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +4.33% per trade.
1 Year
Justin BowersDeutsche Bank
Success Rate
2/10 ratings generated profit
20%
Average Return
-7.31%
reiterated a buy rating 28 days ago
Copying Justin Bowers's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -7.31% per trade.
2 Years
xxx
Success Rate
1/10 ratings generated profit
10%
Average Return
-14.64%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 10.00% of your transactions generating a profit, with an average return of -14.64% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRL Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
0
0
0
0
0
Buy
3
1
1
0
4
Hold
21
23
26
25
20
Sell
3
1
1
0
0
Strong Sell
0
0
0
0
0
total
27
25
28
25
24
In the current month, CRL has received 4 Buy Ratings, 20 Hold Ratings, and 0 Sell Ratings. CRL average Analyst price target in the past 3 months is 157.23.
Each month's total comprises the sum of three months' worth of ratings.

CRL Financial Forecast

CRL Earnings Forecast

Next quarter’s earnings estimate for CRL is $2.50 with a range of $2.46 to $2.57. The previous quarter’s EPS was $2.34. CRL beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year CRL has Outperformed its overall industry.
Next quarter’s earnings estimate for CRL is $2.50 with a range of $2.46 to $2.57. The previous quarter’s EPS was $2.34. CRL beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year CRL has Outperformed its overall industry.

CRL Sales Forecast

Next quarter’s sales forecast for CRL is $983.10M with a range of $972.00M to $992.66M. The previous quarter’s sales results were $984.17M. CRL beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.34% of the time in the same period. In the last calendar year CRL has Outperformed its overall industry.
Next quarter’s sales forecast for CRL is $983.10M with a range of $972.00M to $992.66M. The previous quarter’s sales results were $984.17M. CRL beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.34% of the time in the same period. In the last calendar year CRL has Outperformed its overall industry.

CRL Stock Forecast FAQ

What is CRL’s average 12-month price target, according to analysts?
Based on analyst ratings, Charles River Laboratories Intl’s 12-month average price target is 157.23.
    What is CRL’s upside potential, based on the analysts’ average price target?
    Charles River Laboratories Intl has 16.43% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CRL a Buy, Sell or Hold?
          Charles River Laboratories Intl has a consensus rating of Moderate Buy which is based on 4 buy ratings, 10 hold ratings and 0 sell ratings.
            What is Charles River Laboratories Intl’s price target?
            The average price target for Charles River Laboratories Intl is 157.23. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $182.00 ,the lowest forecast is $100.00. The average price target represents 16.43% Increase from the current price of $135.04.
              What do analysts say about Charles River Laboratories Intl?
              Charles River Laboratories Intl’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of CRL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis